REtroperitoneal SArcoma (RESAR): prospective collection of RPS

• Research type

  Research Study

• Full title

  REtroperitoneal SArcoma (RESAR): prospective collection of retroperitoneal sarcoma patient outcomes

• IRAS ID

  335034

• Contact name

  Samuel Ford

• Contact email

  samuel.ford@uhb.nhs.uk

• Sponsor organisation

  Fondazione IRCCS

• Duration of Study in the UK

  10 years, 0 months, 0 days

• Research summary

  The RESAR platform is dedicated to the collation of data and the study of retroperitoneal, abdominal and pelvic sarcoma. The primary objective for the prospective RESAR Study, is the collation of prospectively collected data which will contribute to the RESAR platform and support with the following:
  - support wider clinical decision-making and resource allocation by the monitoring of epidemiological sarcoma patterns (e.g. increasing incidence of radiation induced sarcoma)
  - Evaluate current treatment outcomes and utilise the inherent differences in specialist centre based care to identify and disseminate best practice in sarcoma patient management
  - Monitor the progress of specialisation and centralisation of sarcoma patient care; develop evidence-based expert consensus guidelines to standardise care of this complex and rare disease globally
  -Facilitate translational scientific research to advance fundamental knowledge and develop novel therapies
  -Develop highly efficient international clinical “trials within a registry”.

  It is intended that specific prospective trials conducted within RESAR (randomised or not) will require individual Ethics approval. In contrast, pure data driven, observational projects, that do not directly influence or modify centre specific patient care are intended to be covered in a generic fashion as part of this IRAS application.

• REC name

  Wales REC 5

• REC reference

  24/WA/0105

• Date of REC Opinion

  9 May 2024

• REC opinion

  Favourable Opinion